MedTrace Logo

Pericapsular Exparel for Pain Relief in Bunionectomy and Related Procedures

NCT02499575 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2017-05-17

Study results available
· View outcomes & findings →

Summary

Exparel is an FDA-approved local anesthetic (bupivacaine), in a long-release formulation. In this study the investigators plan to determine the ability of Exparel to control post-operative pain in common first metatarsophalangeal (MTP) joint procedures (bunion surgery, 1st MTP fusion, and cheilectomy).

Conditions

  • Bunion
  • Hallux Rigidus

Interventions

DRUG

0.5% ropivacaine

Adductor block: 10 mL of 0.5% ropivacaine; popliteal block: 30 mL of 0.5% ropivacaine

DRUG

Exparel

106 mg (8 mL, equivalent to 120 mg bupivacaine HCl)

Sponsors & Collaborators

  • OhioHealth

    lead OTHER

Principal Investigators

  • Christopher Hyer, DPM · OhioHealth

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2016-01-31
Completion
2016-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02499575 on ClinicalTrials.gov